CRISPR/Cas9介导TKI对非小细胞肺癌基因靶向吉非替尼耐药敏感性的影响及其机制

doi:10.13481/j.1671-587x.20190616

摘要/Abstract

摘要： 目的：探讨CRISPR/Cas9介导酪氨酸激酶抑制剂（TKI）对非小细胞肺癌基因靶向吉非替尼耐药敏感性的影响，并阐明其机制。方法：利用CRISPR/Cas9系统建立酪氨酸激酶（TKs）敲除A549细胞株，按照TKI表达情况分为A549、A549TKs^-/+和A549TKs^-/-细胞株。Western blotting法检测细胞株中P53、MDM2、Bcl-2和Bax蛋白表达水平，CCK-8法检测A549、A549TKs^-/+和A549TKs^-/-细胞活性，细胞划痕实验检测A549、A549TKs^-/+和A549TKs^-/-细胞株的细胞迁移情况，流式细胞术检测A549、A549TKs^-/+和A549TKs^-/-细胞凋亡率，克隆形成实验检测细胞集落形成情况。结果：CRISPR/Cas9系统成功建立了TKs敲出A549细胞株，A549、A549TKs^-/+和A549TKs^-/-细胞活性比较差异无统计学意义（P>0.05）；3种细胞凋亡率比较差异无统计学意义（P>0.05），细胞迁移情况变化不大。经6 mol·L^-1吉非替尼干预72 h后，与A549细胞株比较，A549TKs^-/+和A549TKs^-/-细胞株的细胞活性降低（P<0.05），细胞凋亡率升高（P<0.05），细胞划痕愈合率明显降低（P<0.05），细胞迁移能力明显减弱；与A549细胞株比较，A549TKs^-/+和A549TKs^-/-细胞株中P53和Bax蛋白表达水平降低（P<0.05），MDM2和Bcl-2蛋白表达水平明显升高（P<0.05），细胞集落生成率明显降低（P<0.05）。结论：采用吉非替尼对敲除A549细胞株进行干预可以降低细胞活性和迁移能力，升高细胞凋亡率和吉非替尼耐药的敏感性。

关键词: CRISPR/Cas9, 酪氨酸激酶抑制剂, 癌,非小细胞肺, 吉非替尼, 耐药

Abstract: Objective: To investigate the effect of CRISPR/Cas9-mediated tyrosine kinase inhibitor(TKI) on the sensitivity of non-small cell lung cancer gene targeting gefifinib resistance, and to clarify its mechanism. Methods: The A549 cell strains knocked out tyrosine kinases(TKs) by using CRISPR/Cas9 system were established, and then divided into the A549, A549TKs^-/+ and A549 TKs^-/- cell strains according to the expression levels of TKI. The expression levels of P53, MDM2, Bcl-2 and Bax proteins in cell starins were detected by Western blotting method,the activities of A549, A549TKs^-/+, and A549 TKs^-/- cells were detected by CCK-8 method,the cell migration of the A549, A549TKs^-/+, and A549 TKs^-/- cells were detected by cell scratch method, the apoptotic rates of the A549, A549TKs^-/+, and A549 TKs^-/- cells were detected by flow cytometry,and the colony formation status of the A549, A549TKs^-/+, and A549^-/- cells were detected by colony formation assay. Results: The TKs knockout A549 cell strains were successfully established by CRISPR/Cas9 system. There were no statistically significant differences in the activites of the A549, A549TKs^-/+ and A549TKs^-/- cells (P>0.05),there were no significant differences in the apoptostic rates of the A549, A549TKs^-/+ and A549 TKs^-/- cells (P>0.05),and there was no statistically significant difference in the migration of the A549, A549TKs^-/+ and A549TKs^-/- cells. After intervented with gefitinib for 72 h,compared with A549 cell strain, the cell activities of the A549TKs^-/+ and A549TKs^-/- cell strains were significantly decreased(P<0.05),the apoptotic rates were significantly increased (P<0.05), the rates of scratch healing were obviously decreased(P<0.05),and the migration abilities were significantly decreased;compared with A549 cell stain,the expression levels of P53 and Bax proteins in the A549TKs^-/+ and A549TKs^-/- cell strains were significantly decreased (P<0.05),the expression levels of MDM2 and Bcl-2 proteins were significantly increased (P<0.05), and the colony formation rates were significantly decreased (P<0.05). Conclusion: Gefitinib intervention in the knockout A549 cell strain can decrease the cell viability and migration ability and increase the apoptotic rate and sensitivity of gefitinib resistance.

Key words: CRISPR/Cas9, tyrosine kinase inhibitor, non-small cell lung cancer, gefitinib, drug resistance

中图分类号:

R734.2

任爱华, 王大伟. CRISPR/Cas9介导TKI对非小细胞肺癌基因靶向吉非替尼耐药敏感性的影响及其机制[J]. 吉林大学学报(医学版), 2019, 45(06): 1288-1293.

REN Aihua, WANG Dawei. Effect of CRISPR/Cas9-mediated TKI on sensitivity of non-small cell lung cancer gene targeting gefitinib resistance and its mechanism[J]. Journal of Jilin University(Medicine Edition), 2019, 45(06): 1288-1293.

参考文献

[1] 周建英, 刘震天, 陈颖兰. MiRNA-25在非小细胞肺癌吉非替尼耐药细胞中的表达及其作用机制[J]. 实用癌症杂志, 2016, 31(10):1567-1571.
[2] 姜秀秀, 佟金平, 李剑, 等. Mcl-1参与非小细胞肺癌对吉非替尼耐药的实验研究[J]. 现代生物医学进展, 2018, 18(9):119-122.
[3] 张立文. 吉非替尼对非小细胞肺癌患者免疫功能的影响[J]. 中国药物与临床, 2018, 18(9):96-98.
[4] WANG N, ZHANG T. Downregulation of microRNA-135 promotes sensitivity of non-small cell lung cancer to gefitinib by targeting TRIM16[J]. Oncol Res, 2018, 26(7):1005-1014.
[5] 张钰, 周建国, 马虎. 非小细胞肺癌分子靶向治疗及其耐药[J]. 国际肿瘤学杂志, 2016, 43(1):45-48.
[6] 赵佳, 陈建业, 汤建才. 非小细胞肺癌吉非替尼耐药机制及治疗研究进展[J]. 中国现代应用药学, 2017, 53(6):139-143.
[7] 皮灿, 张一辰, 徐崇锐,等. 表皮生长因子受体敏感突变阳性非小细胞肺癌耐药后的精准治疗[J]. 中华肿瘤杂志, 2017, 39(2):94-97.
[8] 王筱雨, 李士军. MALAT1降低非小细胞肺癌对吉非替尼药物敏感性的研究[J]. 中华检验医学杂志, 2017, 40(1):55-59.
[9] LIU W, NING J, LI C, et al. Overexpression of Sphk2 is associated with gefitinib resistance in non-small cell lung cancer[J]. Tumor Biol, 2016, 37(5):6331-6336.
[10] KAZANDJIAN D, BLUMENTHAL G M, YUAN W, et al. FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer[J]. Clin Cancer Res, 2016, 22(6):1307-1312.
[11] 虞莉, 黄沙, 吕望,等. 上皮间质转化在非小细胞肺癌EGFR-TKIs耐药中的研究进展[J]. 中国肺癌杂志, 2018, 21(12):29-33.
[12] 谢刚强, 刘春田, 张永庆,等. 吉非替尼治疗非小细胞肺癌患者的临床疗效分析[J]. 现代生物医学进展, 2016(34):6754-6757.
[13] 王海霞, 帅帅, 廖雪阳,等. TIP30逆转人非小细胞肺癌吉非替尼耐药的实验研究[J]. 中国肿瘤临床, 2018, 45(18):14-19.
[14] 林顺欢, 江冠铭, 刘淳, 等. 贝伐珠单抗联合EGFR-TKI治疗EGFR外显子19或21突变晚期非小细胞肺癌的疗效差异[J]. 新医学, 2016, 47(7):472-476.
[15] 臧家兰, 胡勇, 秦晓冰,等. 脂多糖对核转录因子-κB的激活在人肺非小细胞肺癌获得性耐药细胞中的作用[J]. 国际免疫学杂志, 2017, 40(03):238-242.
[16] HAN S Y, ZHAO W, HAN H B, et al. Marsdenia tenacissima extract overcomes Ax1-and Met-mediated erlotinib and gefitinib cross-resistance in non-small cell lung cancer cells[J]. Oncotarget, 2017, 8(34):56893.
[17] PAZ-ARES L, TAN E H, O’Byrne K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial[J]. Ann Oncol, 2017, 28(2):270-277.
[18] YANG J J, ZHOU Q, YAN H H, et al. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations[J]. Br J Cancer, 2017, 116(5):568-574.
[19] XUETING C, JIE Y, CHUNPING H U, et al. Dihydroartemisinin enhances the sensitivity of gefitinib in non-small cell lung cancer cells by inhibiting STAT3[J]. Chin Sci Bull, 2017, 62(18):2013-2019.
[20] SCHULER M, YANG J, PARK K, et al. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase Ⅲ randomized LUX-Lung 5 trial[J]. Ann Oncol, 2016, 27(3):417-423.